PM
BEAM icon

Prosight Management’s Beam Therapeutics BEAM Stock Holding History

Prosight Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$816K – 40
2020
Q4 		$816K Buy
+10,000
New +$492K 0.38% 38

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prosight Management's BEAM Position: Q2 2021 in Review

Prosight Management sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 17,000 shares — an estimated $1.36M sold.

Prosight Management first reported a position in BEAM in Q1 2021 and held it in 1 quarter. The position peaked at $1.36M in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Prosight Management reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Prosight Management sold 17,000 Beam Therapeutics shares in Q2 2021, an estimated $1.36M.
  • Prosight Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 1 quarter.
  • Prosight Management's Beam Therapeutics position peaked at $1.36M in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.